Patents by Inventor Shiv K. Srivastava
Shiv K. Srivastava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913076Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer, including certain gene expression profiles that differentiate between subjects of African and Caucasian descent and other gene expression profiles that are common to subjects of both African and Caucasian descent. The gene expression profiles can be measured at the nucleic acid or protein level and used to stratify prostate cancer based on ethnicity. The gene expression profiles can also be used to identify a subject for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and an array comprising probes for detecting the unique gene expression profiles associated with prostate cancer in subjects of African and/or Caucasian descent.Type: GrantFiled: May 8, 2018Date of Patent: February 27, 2024Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Indu Kohaar
-
Patent number: 11648239Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.Type: GrantFiled: January 26, 2021Date of Patent: May 16, 2023Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
-
Publication number: 20230119558Abstract: The present disclosure provides DNA Damage Repair gene (DDRG) panels and methods of using the same for genetic testing and genetic counseling to predict a predisposition to cancer, including prostate cancer. The gene panels can be used to stratify prostate cancer patients according to disease severity and/or aggressiveness or to identify and/or stratify a patient for cancer treatment. Also provided are kits for use in predicting, diagnosing, and/or prognosing cancer.Type: ApplicationFiled: March 5, 2021Publication date: April 20, 2023Inventors: Gyorgy PETROVICS, Shiv K. SRIVASTAVA
-
Publication number: 20220033913Abstract: The present disclosure provides methods of identifying or characterizing prostate cancer comprising detecting in a biological sample the presence or absence of a genomic rearrangement that results in a deletion of an LSAMP gene and detecting in a biological sample the presence or absence of a genomic rearrangement that results in a deletion of a CHD1 gene. In certain embodiments, the patient self-identifies as being of African descent. Also disclosed herein are methods of testing for the presence of genomic rearrangements in an LSAMP gene and a CHD1 gene in a biological sample. The LSAMP and CHD1 genomic rearrangements serves as a biomarker for prostate cancer and can be used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer and/or identify a patient for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and methods of selecting a targeted prostate cancer treatment for a patient.Type: ApplicationFiled: December 12, 2019Publication date: February 3, 2022Inventors: Albert DOBI, Gyorgy PETROVICS, Shiv K. SRIVASTAVA, Hua LI, Zoltan SZALLASI
-
Publication number: 20210299106Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.Type: ApplicationFiled: January 26, 2021Publication date: September 30, 2021Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
-
Publication number: 20210108271Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer, including certain gene expression profiles that differentiate between subjects of African and Caucasian descent and other gene expression profiles that are common to subjects of both African and Caucasian descent. The gene expression profiles can be measured at the nucleic acid or protein level and used to stratify prostate cancer based on ethnicity. The gene expression profiles can also be used to identify a subject for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and an array comprising probes for detecting the unique gene expression profiles associated with prostate cancer in subjects of African and/or Caucasian descent.Type: ApplicationFiled: May 8, 2018Publication date: April 15, 2021Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Indu Kohaar
-
Patent number: 10711311Abstract: The present disclosure provides genomic arrangements of the chromosome 3q13 region that are associated with prostate cancer, such as rearrangements between the ZBTB20 and LSAMP genes, including gene fusions between the ZBTB20 gene and the LSAMP gene and deletions spanning both genes. The ZBTB20/LSAMP genomic rearrangement serves as a biomarker for prostate cancer and can be used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer and/or identify a patient for prostate cancer treatment. Another aspect involves discovering that deletions of the PTEN gene are observed predominately in prostate cancer from subjects of Caucasian descent. Also provided are kits for diagnosing and prognosing prostate cancer.Type: GrantFiled: December 30, 2014Date of Patent: July 14, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv K. Srivastava, Albert Dobi, Gyorgy Petrovics, Thomas Werner, Martin Seifert, Matthias Scherf
-
Publication number: 20190336485Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.Type: ApplicationFiled: February 15, 2019Publication date: November 7, 2019Applicant: The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.Inventors: Albert L. DOBI, Clifton L. DALGARD, Shiv K. SRIVASTAVA
-
Patent number: 10238639Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.Type: GrantFiled: September 9, 2016Date of Patent: March 26, 2019Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
-
Patent number: 10081842Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer. The gene expression profiles can be used to detect prostate cancer cells in a sample and to distinguish between well differentiated (WD) prostate cancer and poorly differentiated (PD) prostate cancer. Also provided is an array comprising oligonucleotide probes for detecting the unique gene signature associated with WD and/or PD prostate cancer.Type: GrantFiled: August 6, 2013Date of Patent: September 25, 2018Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv K. Srivastava, Gyorgy Petrovics
-
Publication number: 20180169074Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.Type: ApplicationFiled: September 9, 2016Publication date: June 21, 2018Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Albert L. DOBI, Clifton L. DALGARD, Shiv K. SRIVASTAVA
-
Publication number: 20170030915Abstract: Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells.Type: ApplicationFiled: May 5, 2016Publication date: February 2, 2017Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Shyh-Han Tan, Kristen Nickens
-
Publication number: 20160326594Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer, including certain gene expression profiles that differentiate between subjects of African and Caucasian descent and other gene expression profiles that are common to subjects of both African and Caucasian descent. The gene expression profiles can be measured at the nucleic acid or protein level and used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer. The gene expression profiles can also be used to identify a subject for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and an array comprising probes for detecting the unique gene expression profiles associated with prostate cancer in subjects of African or Caucasian descent.Type: ApplicationFiled: December 29, 2014Publication date: November 10, 2016Inventors: Shiv K. Srivastava, Albert Dobi, Gyorgy Petrovics, Thomas Werner, Martin Seifert, Matthias Scherf
-
Publication number: 20160326595Abstract: The present disclosure provides genomic arrangements of the chromosome 3q13 region that are associated with prostate cancer, such as rearrangements between the ZBTB20 and LSAMP genes, including gene fusions between the ZBTB20 gene and the LSAMP gene and deletions spanning both genes. The ZBTB20/LSAMP genomic rearrangement serves as a biomarker for prostate cancer and can be used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer and/or identify a patient for prostate cancer treatment. Another aspect involves discovering that deletions of the PTEN gene are observed predominately in prostate cancer from subjects of Caucasian descent. Also provided are kits for diagnosing and prognosing prostate cancer.Type: ApplicationFiled: December 30, 2014Publication date: November 10, 2016Inventors: Shiv K. Srivastava, Albert Dobi, Gyorgy Petrovics, Thomas Werner, Martin Seifert, Matthias Scherf
-
Patent number: 9335327Abstract: Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis.Type: GrantFiled: August 8, 2012Date of Patent: May 10, 2016Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Shyh-Han Tan, Kristen Nickens
-
Publication number: 20160115481Abstract: Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1 and ERG genes.Type: ApplicationFiled: October 30, 2015Publication date: April 28, 2016Inventors: Shiv K. Srivastava, Albert L. Dobi, Taduru Sreenath, Gyorgy Petrovics, Chen Sun
-
Publication number: 20150176078Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer. The gene expression profiles can be used to detect prostate cancer cells in a sample and to distinguish between well differentiated (WD) prostate cancer and poorly differentiated (PD) prostate cancer. Also provided is an array comprising oligonucleotide probes for detecting the unique gene signature associated with WD and/or PD prostate cancer.Type: ApplicationFiled: August 6, 2013Publication date: June 25, 2015Inventors: Shiv K. Srivastava, Gyorgy Petrovics
-
Publication number: 20140193833Abstract: Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis.Type: ApplicationFiled: August 8, 2012Publication date: July 10, 2014Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Shiv K. Srivastava, Petrovics Gyorgy, Shyh-Han Tan, Kristen Nickens